<DOC>
	<DOCNO>NCT01866839</DOCNO>
	<brief_summary>Background : - Researchers work make stem cell transplant procedure safer effective . One complication transplant graft-versus-host disease ( GVHD ) . This complication happen certain white blood cell donor attack recipient 's body . Researchers want test blood separator machine may help remove donor 's white blood cell transplant . They study donor recipient stem cell transplant see well process prevent GVHD complication . Objectives : - To see new blood separator machine improve outcome stem cell transplant . Eligibility : - Individuals 10 75 year age stem cell transplant leukemia blood-related cancer . - Donors stem cell transplant . Design : - Recipients donor screen physical exam medical history . - Donors two blood collection procedure . The first collect white blood cell , return rest blood . After first collection , participant filgrastim injection help stem cell enter blood . Then , second blood collection stem cell . - Recipients radiation chemotherapy prepare stem cell transplant . They stem cell transplant donor cell treat blood separator machine . - Recipients monitor closely procedure . They may receive donor 's white blood cell need fight serious infection . - Recipients regular standard care transplant . Blood sample take side effect monitor treat .</brief_summary>
	<brief_title>Preventing Stem Cell Transplant Complications With Blood Separator Machine</brief_title>
	<detailed_description>Peripheral blood stem cell transplant research carry NHLBI BMT Unit focus transplant technique design decrease graft versus host disease ( GVHD ) , increase graft-versus-leukemia ( GVL ) effect reduce risk post-transplant graft rejection . Through incremental transplant clinical trial show control stem cell ( CD34+ cell ) T lymphocyte ( CD3+ cell ) dose , severe GVHD reduce whilst beneficial GVL effect preserve . We find T cell deplete transplant use Nexell/Baxter Isolex 300i system subsequently , Miltenyi CliniMACS [ register ] CD34+ system obtain high CD34+ dos deplete lymphocyte safe administer associate less severe acute GVHD promising response rate overall survival . Our previous trial help u create transplant environment ( significant lymphodepletion minimal post transplant immunosuppression ) make ideal platform adoptive cellular immunotherapy . Adoptive cell transfer passive transfer immune cell , new recipient host goal transfer immunologic functionality characteristic new host . This protocol design evaluate safety efficacy Miltenyi CliniMACS [ register ] CD 34 selection system HLA-matched sibling allogeneic peripheral blood stem cell transplant . The manipulation graft primary research intervention , subject IDE # 15632 , aspects clinical management protocol standard care . The target CD34+ dose range &gt; 3 x 10 ( 6 ) /kg target CD3+ dose range 5 x 10 ( 4 ) /kg 1 x 10 ( 6 ) /kg . Once demonstrate adequacy platform engraftment absence significant GVHD ten consecutive recipient , seek IRB permission proceed plan adoptive cellular therapy . The protocol accrue 96 transplant recipient age 10-80 hematological malignancy HLA-matched sibling donor , allogeneic stem cell transplantation HLA-matched sibling would routinely indicate . Diagnostic category include acute chronic leukemia , myelodysplastic syndrome , lymphoma , multiple myeloma myeloproliferative syndrome . Subjects receive myeloablative conditioning regimen cyclophosphamide ( 120 mg/kg total ) , fludarabine ( 125 mg/m ( 2 ) total ) total body irradiation ( 1200 cGy lung shield 600 cGy ) , follow infusion stem cell product select CD34+ progenitor use Miltenyi CliniMACS [ register ] system . Older subject receive low dose irradiation ( 800 600 cGy base age ) reduce regimen intensity . The overall objective ass feasibility use system platform cellular immunotherapy initiative . The primary study endpoint overall survival day +200 . Stopping criterion safety monitor non-relapse mortality day +200 late disease free survival 2 year . Secondary endpoint standard transplant outcome variable non-hematologic toxicity , incidence severity acute chronic GVHD relapse disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>INCLUSION CRITERIA RECIPIENT 5.1.1 Ages 1080 year inclusive 5.1.2 Any one follow hematologic condition , confirm pathology , meet standard indication allogeneic stem cell transplant : 5.1.2.1 Chronic myelogenous leukemia ( CML ) : Subjects age 21 chronic phase OR Subjects age 1080 chronic phase fail intolerant treatment second generation tyrosine inhibitor OR Subjects age 1080 accelerate phase blast transformation . OR 5.1.2.2 Acute lymphoblastic leukemia ( ALL ) : category : Adult ALL include standard risk ; Pediatric ALL first remission highrisk feature ( present leukocyte count &gt; 100,000/cu mm , karyotype ( 9 ; 22 ) , t4 , t19 , t11 , biphenotypic leukemia ) . All second subsequent remission , primary induction failure , partially respond untreated relapse . OR 5.1.2.3 Acute myelogenous leukemia ( AML ) : AML first remission except AML good risk karyotype : AML M3 ( t15 ; 17 ) , AML M4Eo ( inv 16 ) , ckit unmutated AML ( 8 ; 21 ) . All AML second subsequent remission , primary induction failure resistant relapse . OR 5.1.2.4 Myelodysplastic syndrome ( MDS ) : category refractory anemia transfusion dependence , refractory anemia ANC &lt; 500/microL , refractory anemia excess blast , transformation acute leukemia , chronic myelomonocytic leukemia , atypical MDS/myeloproliferative syndrome . OR 5.1.2.5 Myeloproliferative disorder include atypical ( Phnegative ) chronic myeloid neutrophilic leukemia , progress myelofibrosis , polycythemia vera , essential thrombocythemia either transformation acute leukemia progressive transfusion requirement pancytopenia . OR 5.1.2.6 Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000 / microl ) anemia ( less equal 10g/dl ) due recent chemotherapy . OR 5.1.2.7 NonHodgkin lymphoma include Mantle cell lymphoma relapse refractory standard care treatment . OR 5.1.2.8 Multiple myeloma , Waldenstroms macroglobulinemia , unresponsive relapse follow standard care treatment . OR 5.1.2.9 Hodgkin 's Lymphoma relapse follow autologous transplant . OR 5.1.2.10 Other rare hematologic malignancy hematopoietic stem cell transplantation perform offer durable remission option potential cure . Chemotherapyresistant multisystem Langerhans cell histiocytosis ( MSLCH ) especially involve organ like bone marrow , liver , spleen , lung Aggressive systemic mastocytosis , mast cell leukemia ( MCL ) first CR ( CR1 ) Hypereosinophilic syndrome fail imatinib therapy FIP1L1PDGFRanegative patient develop endorgan dysfunction Adult Tcell leukemia/lymphoma first diagnosis Refractory disseminate nasaltype extranodal NK/Tlymphoma aggressive Natural killer cell leukemia/lymphoma Mycosis fungoides S ( SqrRoot ) ( Copyright ) zary syndrome failure two three initial therapy Primary relapse refractory Angioimmunoblastic Tcell lymphoma first diagnosis Hepatosplenic Tcell lymphoma ( gamma/delta Tcell lymphoma ) first diagnosis Tcell prolymphocytic leukemia first diagnosis Subcutaneous panniculitic Tcell lymphoma first diagnosis Hematodermic neoplasm ( blastic natural killer cell lymphoma Blastic plasmacytoid dendritic cell neoplasm ) first diagnosis 5.1.3 HLA identical ( 6/6 ) relate donor . 5.1.4 For adult : ability comprehend investigational nature study provide inform consent . For minor : write informed consent one parent guardian . Informed oral assent minor : process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA RECIPIENT ( follow ) 5.2.1 Major anticipated illness organ failure incompatible survival transplant 5.2.2 Severe psychiatric illness mental deficiency sufficiently severe make compliance transplant treatment unlikely make informed consent impossible . 5.2.3 Positive pregnancy test woman childbearing age 5.2.4 DLCO adjust Hb ventilation &lt; 50 % predict 5.2.5 Left ventricular ejection fraction &lt; 40 % ( evaluated ECHO ) &lt; 30 % ( evaluated MUGA ) 5.2.6 AST/SGOT &gt; 10 time ULN 5.2.7 Total bilirubin &gt; 5 time ULN 5.2.8 Estimated GFR &lt; 15 mL/min 5.2.9 Recipients active infection HIV active hepatitis C ( HCV ) INCLUSION CRITERIA DONOR 5.3.1 Related donor , HLA identical ( 6/6 ) recipient 5.3.2 Weight great equal 18 kg 5.3.3 Age great equal 2 less equal 80 year old 5.3.4 For adult : ability comprehend investigational nature study provide inform consent . For minor : write informed consent one parent guardian inform assent : The process explain minor level complexity appropriate age ability comprehend . EXCLUSION CRITERIA DONOR ( follow ) 5.4.1 Pregnant breastfeeding . Lactating donor permit provide breast milk discard day filgrastim ( GCSF ) give 5.4.2 Unfit receive GCSF undergo apheresis ( abnormal blood count , history stroke , uncontrolled hypertension ) 5.4.3 Sickling hemoglobinopathy include HbSS , HbSC 5.4.4 Donors positive HIV , active hepatitis B ( HBV ) , hepatitis C ( HCV ) human Tcell lymphotropic virus ( HTLVI/II ) 5.4.5 Severe psychiatric illness mental deficiency sufficiently severe make compliance donation process unlikely , make informed consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 6, 2017</verification_date>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Myelodyplastic Syndrome ( MDS )</keyword>
</DOC>